Edgar H Adams

Summary

Affiliation: Covance Laboratories
Country: USA

Publications

  1. ncbi A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain
    Edgar H Adams
    Edgar Adams Consulting, Covance, Princeton, New Jersey 08540, USA
    J Pain Symptom Manage 31:465-76. 2006
  2. ncbi A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study
    Edgar H Adams
    Epidemiology, Covance, Princeton, New Jersey, USA
    Pain Pract 6:254-64. 2006
  3. ncbi Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007
    Zdravko P Vassilev
    Covance Inc, Princeton, NJ 08540, USA
    Am J Health Syst Pharm 66:481-7. 2009
  4. ncbi An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride)
    George E Woody
    Treatment Research Institute, School of Medicine, Philadelphia Va University of Pennsylvania, 600 Public Ledger Building, 150 South Independence Mall W, Philadelphia, PA 19106 3475, USA
    Drug Alcohol Depend 72:163-8. 2003
  5. ncbi Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004
    Theodore J Cicero
    Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Pharmacoepidemiol Drug Saf 14:851-9. 2005
  6. ncbi Foundations of opioid risk management
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:103-18. 2007
  7. ncbi Challenges in the development of prescription opioid abuse-deterrent formulations
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:648-60. 2007
  8. ncbi The Diversion of Ultram, Ultracet, and generic tramadol HCL
    James A Inciardi
    University of Delaware Research Center, Coral Gables, FL 33134, USA
    J Addict Dis 25:53-8. 2006
  9. ncbi Tramadol abuse and dependence among physicians
    Edgar H Adams
    JAMA 293:1977; author reply 1977-8. 2005
  10. ncbi Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur
    Edward C Senay
    Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA
    Drug Alcohol Depend 69:233-41. 2003

Detail Information

Publications10

  1. ncbi A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain
    Edgar H Adams
    Edgar Adams Consulting, Covance, Princeton, New Jersey 08540, USA
    J Pain Symptom Manage 31:465-76. 2006
    ....
  2. ncbi A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study
    Edgar H Adams
    Epidemiology, Covance, Princeton, New Jersey, USA
    Pain Pract 6:254-64. 2006
    ..These results were achieved with a stable daily morphine dose over the three-month study period...
  3. ncbi Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007
    Zdravko P Vassilev
    Covance Inc, Princeton, NJ 08540, USA
    Am J Health Syst Pharm 66:481-7. 2009
    ..The likelihood of hospitalization caused by adverse drug reactions (ADRs) from commonly implicated therapeutic groups is discussed...
  4. ncbi An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride)
    George E Woody
    Treatment Research Institute, School of Medicine, Philadelphia Va University of Pennsylvania, 600 Public Ledger Building, 150 South Independence Mall W, Philadelphia, PA 19106 3475, USA
    Drug Alcohol Depend 72:163-8. 2003
    ..Assess the validity of medical products reporting program (MEDWatch) reports of abuse/dependence and withdrawal associated with Ultram (tramadol)...
  5. ncbi Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004
    Theodore J Cicero
    Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Pharmacoepidemiol Drug Saf 14:851-9. 2005
    ..This provided a unique opportunity to study the potential changes in abuse as the generic and combination products became available...
  6. ncbi Foundations of opioid risk management
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:103-18. 2007
    ..Limitations of current approaches, and emerging directions in opioid risk management, are also presented...
  7. ncbi Challenges in the development of prescription opioid abuse-deterrent formulations
    Nathaniel P Katz
    Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 23:648-60. 2007
    ....
  8. ncbi The Diversion of Ultram, Ultracet, and generic tramadol HCL
    James A Inciardi
    University of Delaware Research Center, Coral Gables, FL 33134, USA
    J Addict Dis 25:53-8. 2006
    ..Survey data suggest that the diversion of Ultram and other tramadol products is low, and overall, diversion investigators did not consider tramadol to be a problem in their respective jurisdictions...
  9. ncbi Tramadol abuse and dependence among physicians
    Edgar H Adams
    JAMA 293:1977; author reply 1977-8. 2005
  10. ncbi Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur
    Edward C Senay
    Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA
    Drug Alcohol Depend 69:233-41. 2003
    ..These results indicate that physicians and other healthcare professionals need to be aware of the potential of Ultram to induce withdrawal of the classical opioid type, and that atypical withdrawal may also occur...